First National Bank of Omaha Purchases Shares of 35,533 Quest Diagnostics Incorporated $DGX

First National Bank of Omaha purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 35,533 shares of the medical research company’s stock, valued at approximately $7,536,000.

Several other hedge funds also recently modified their holdings of the stock. Davis Selected Advisers boosted its holdings in shares of Quest Diagnostics by 16.8% in the 4th quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock valued at $275,895,000 after buying an additional 228,271 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in Quest Diagnostics by 178.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock worth $29,847,000 after buying an additional 110,280 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Quest Diagnostics by 39.1% during the second quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company’s stock worth $3,265,000 after acquiring an additional 4,334 shares in the last quarter. Advisors Capital Management LLC raised its position in Quest Diagnostics by 5.4% during the fourth quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock worth $54,460,000 after acquiring an additional 16,194 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at $92,000. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Trading Up 0.5%

DGX stock opened at $236.71 on Wednesday. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $240.13. The stock has a market cap of $26.13 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company has a fifty day moving average price of $217.00 and a two-hundred day moving average price of $204.06. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Equities analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be issued a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.5%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Insiders Place Their Bets

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock worth $3,947,088 over the last three months. Insiders own 0.88% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on DGX. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, July 29th. Evercore set a $225.00 target price on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Truist Financial lifted their price target on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $235.31.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.